| Literature DB >> 35710920 |
Young Il Won1, Yunhee Choi2, Woon Tak Yuh1, Shin Won Kwon1, Chi Heon Kim1,3, Seung Heon Yang1, Chun Kee Chung4,5,6.
Abstract
MRI is the primary diagnostic modality for spinal cord tumors. However, its validity has never been vigorously scrutinized in daily routine clinical practice, where MRI tissue diagnosis is usually not a single one but multiple ones with several differential diagnoses. Here, we aimed to assess the validity of MRI in terms of predicting the pathology and location of the tumor in routine clinical settings. We analyzed 820 patients with primary spinal cord tumors, who have a pathological diagnosis and location in the operation record which were confirmed. We modified traditional measures for validity based upon a set of diagnoses instead of a single diagnosis. Sensitivity and specificity and positive and negative predictabilities were evaluated for the tumor location and pathology. For tumor location, 456 were intradural extramedullary; 165 were intramedullary, and 156 were extradural. The overall sensitivity and specificity were over 90.0%. However, the sensitivity became lower when the tumor resided simultaneously in two spaces such as in the intradural-and-extradural or intramedullary-and-extramedullary space (54.6% and 30.0%, respectively). Most common pathology was schwannoma (n = 416), followed by meningioma (114) and ependymoma (87). Sensitivities were 93.3%, 90.4%, and 89.7%, respectively. Specificities were 70.8%, 82.9%, and 76.0%. In rare tumors such as neurofibromas, and diffuse midline gliomas, the sensitivity was much lower (less than 30%). For common locations and pathologies, the validity of MRI is generally acceptable. However, for rare locations and pathologies, MRI diagnosis still needs some improvement.Entities:
Mesh:
Year: 2022 PMID: 35710920 PMCID: PMC9203586 DOI: 10.1038/s41598-022-13881-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
The validity of MRI for the location of the tumor.
| Reference standard | MRI report | Validity (95% confidence interval) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| IDEM | IM | ED | ID&ED | IM&EM | Total (%) | Sensitivity | Specificity | PPV | NPV | |
| IDEM | 425 | 17 | 7 | 5 | 2 | 456 (55.6) | 0.932 (0.909, 0.955) | 0.92 (0.893, 0.948) | 0.936 (0.914, 0.959) | 0.915 (0.887, 0.944) |
| IM | 10 | 154 | 0 | 0 | 1 | 165 (20.1) | 0.933 (0.895, 0.971) | 0.97 (0.956, 0.983) | 0.885 (0.838, 0.932) | 0.983 (0.973, 0.993) |
| ED | 7 | 1 | 138 | 10 | 0 | 156 (19.0) | 0.885 (0.835, 0.935) | 0.977 (0.966, 0.989) | 0.902 (0.855, 0.949) | 0.973 (0.961, 0.985) |
| ID&EDa | 7 | 0 | 8 | 18 | 0 | 33 (4.0) | 0.546 (0.376, 0.715) | 0.981 (0.971, 0.991) | 0.546 (0.376, 0.715) | 0.981 (0.971, 0.991) |
| IM&EM | 5 | 2 | 0 | 0 | 3 | 10 (1.2) | 0.3 (0.016, 0.584) | 0.996 (0.989, 0.999) | 0.5 (0.1, 0.9) | 0.991 (0.985, 0.998) |
| Total | 820 | 0.9 (0.88, 0.921) | 0.975 (0.969, 0.980) | 0.9 (0.88, 0.921) | 0.975 (0.969, 0.980) | |||||
IDEM inradural extra, IM intramedullary, ED extradural, ID&ED both intradural and extradural, IM&EM both intramedullary and extramedullary, PPV positive predictive value, NPV negative predictive value.
Frequency of tumors by location.
| Tumor type | No. of cases | Percentage | Location | ||||
|---|---|---|---|---|---|---|---|
| IDEM | IM | ED | ID&ED | IM&EM | |||
| Schwannoma | 416 | 50.73 | 274 (60.1%)* | 14 (8.5%) | 101 (64.7%)* | 23 (69.7%)* | 4 (40.0%)* |
| Meningioma | 114 | 13.9 | 108 (23.7%)* | 2 (1.3%) | 4 (12.1%) | ||
| Ependymoma | 87 | 10.61 | 17 (3.7%) | 68 (41.2%)* | 2 (20.0%) | ||
| Hemangioblastoma | 28 | 3.41 | 5 (1.1%) | 22 (13.3%)* | 1 (10.0%) | ||
| Cavernous malformation | 27 | 3.29 | 1 (0.2%) | 13 (7.9%) | 13 (8.3%)* | ||
| Benign cyst | 22 | 2.68 | 12 (2.6%) | 2 (1.2%) | 8 (5.1%) | ||
| Neurofibroma | 17 | 2.07 | 4 (0.9%) | 10 (6.4%) | 2 (6.1%) | 1 (10.0%) | |
| Astrocytoma | 13 | 1.59 | 13 (7.9%) | ||||
| Diffuse midline glioma | 10 | 1.22 | 10 (6.1%) | ||||
| Capillary hemangioma | 8 | 0.98 | 6 (1.3%) | 2 (1.2%) | |||
| Ganglioneuroma | 8 | 0.98 | 2 (0.4%) | 2 (1.3%) | 4 (12.1%) | ||
| Hemangiopericytoma | 7 | 0.85 | 4 (0.9%) | 2 (1.3%) | 1 (10.0%) | ||
| Angiolipoma | 5 | 0.61 | 1 (0.6%) | 4 (2.6%) | |||
| Chordoma | 5 | 0.61 | 5 (3.2%) | ||||
| Dermoid/Epidermoid cyst | 4 | 0.49 | 3 (0.7%) | 1 (0.6%) | |||
| Hematoma | 4 | 0.49 | 1 (0.2%) | 3 (1.8%) | |||
| Malignant peripheral nerve sheath tumor | 4 | 0.49 | 2 (0.4%) | 1 (0.6%) | 1 (10.0%) | ||
| Glioblastoma | 3 | 0.37 | 1 (0.2%) | 2 (1.2%) | |||
| Inflammation | 3 | 0.37 | 3 (0.7%) | ||||
| Lymphoma | 3 | 0.37 | 3 (1.8%) | ||||
| Myelitis | 3 | 0.37 | 3 (1.8%) | ||||
| Paraganglioma | 3 | 0.37 | 3 (0.7%) | ||||
| Venous malformation | 3 | 0.37 | 1 (0.6%) | 2 (1.3%) | |||
| Lipoma | 2 | 0.24 | 2 (0.4%) | ||||
| Metastasis | 2 | 0.24 | 1 (0.2%) | 1 (0.6%) | |||
| Teratoma | 2 | 0.24 | 2 (0.4%) | ||||
| Glioneuronal tumor | 2 | 0.24 | 2 (1.2%) | ||||
| Abscess | 1 | 0.12 | 1 (0.6%) | ||||
| Alveolar soft part sarcoma | 1 | 0.12 | 1 (0.6%) | ||||
| Benign notochordal cell tumor | 1 | 0.12 | 1 (0.6%) | ||||
| Fibrosclerosis | 1 | 0.12 | 1 (0.6%) | ||||
| Ganglioglioma | 1 | 0.12 | 1 (0.6%) | ||||
| Germinoma | 1 | 0.12 | 1 (0.6%) | ||||
| Inflammatory myofibroblastic tumor | 1 | 0.12 | 1 (0.2%) | ||||
| Leiomyosarcoma | 1 | 0.12 | 1 (0.2%) | ||||
| Multiple myeloma | 1 | 0.12 | 1 (0.6%) | ||||
| Nerve sheath myxoma | 1 | 0.12 | 1 (0.2%) | ||||
| Neurocysticercosis | 1 | 0.12 | 1 (0.2%) | ||||
| Oligodendroglioma | 1 | 0.12 | 1 (0.6%) | ||||
| Sarcoma | 1 | 0.12 | 1 (0.6%) | ||||
| Schwann cell onion bulb tumor | 1 | 0.12 | 1 (0.2%) | ||||
| Vascular malformation | 1 | 0.12 | 1 (0.6%) | ||||
| Total | 820 | 456 | 165 | 156 | 33 | 10 | |
Asterisk indicates the two most common tumors by location.
Figure 1The validity of MRI for pathology.
Consistency of MRI and pathology in each differential diagnosis.
| No. of cases | |
|---|---|
| 682 | |
| 1st differential diagnosis | 585 (85.8%) |
| 2nd differential diagnosis | 87 (12.8%) |
| 3rd differential diagnosis | 7 (1.0%) |
| 4th differential diagnosis | 3 (0.4%) |
| False negative | 138 |
| Total | 820 |
Differentiation of schwannomas from meningiomas and ependymomas from other gliomas.
| Sensitivitya | Specificityb | Accuracy | Cohen's Kappac | |
|---|---|---|---|---|
| Overall | 0.876 (0.837, 0.915) | 0.861 (0.796, 0.926) | 0.872 (0.838, 0.905) | 0.7 (0.622, 0.777) |
| Indistinguishable | 0.675 (0.574, 0.775) | 0.679 (0.506, 0.852) | 0.676 (0.589, 0.763) | 0.291 (0.118, 0.464) |
| Overall | 0.9 (0.83, 0.97) | 0.6 (0.408, 0.792) | 0.821 (0.744, 0.898) | 0.52 (0.321, 0.719) |
| Indistinguishable | 0.833 (0.712, 0.955) | 0.471 (0.233, 0.708) | 0.717 (0.596, 0.838) | 0.319 (0.046, 0.592) |
Validities and their 95% confidence intervals (in parentheses).
aThe sensitivity of schwannoma and ependymoma (specificity of meningioma and other glioma).
bThe specificity of schwannoma and ependymoma (sensitivity of meningioma and other glioma).
cCohen's Kappa coefficient between MRI report and pathologic report.
Figure 2Validity according to the period of MRI examinations. (a) For the location, sensitivity and specificity showed no significant difference before and after 2012 (P = 0.943, 0.134). (b) For the diagnosis, there was no significant change in sensitivity and specificity ((P = 0.264, 0.581).
Validity according to neuroradiologist.
| Type | Neuroradiologist | p-value | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| Sensitivity | 0.889 (0.839, 0.939) | 0.932 (0.885, 0.978) | 0.841 (0.771, 0.912) | 0.921 (0.864, 0.978) | 0.13 |
| Specificity | 0.972 (0.959, 0.985) | 0.983 (0.971, 0.995) | 0.960 (0.942, 0.979) | 0.980 (0.966, 0.995) | 0.16 |
| Sensitivity | 0.921 (0.873, 0.968) | 0.969 (0.934, 1.004) | 0.933 (0.879, 0.986) | 0.924 (0.864, 0.984) | 0.48 |
| Specificity | 0.893 (0.871, 0.914) | 0.848 (0.819, 0.877) | 0.922 (0.9, 0.945) | 0.932 (0.876, 0.931) | < 0.001* |
Asterisk indicates statistical significance.